Ambu A/S: Capital increase in connection with exercise of warrants issued
Ambu A/S: Capital increase in connection with exercise of warrants issued
Ambu A/S issued 419,500 warrants in 2016. Each warrant entitled the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 71 individuals participated in the 2016 scheme.
Ambu A/S在2016年發行了41.95萬份權證。每份認股權證持有人有權認購一股面值為0.50丹麥克朗的B類股票。71人蔘與了2016年的計劃。
For the 2016 scheme the vesting period was three years, and the scheme could therefore be exercised in the trading window that opened on 8 February 2022 in connection with Ambu's interim financial report for Q1 2021/22.
對於2016年計劃，歸屬期限為三年，因此該計劃可以在2022年2月8日開放的交易窗口中與Ambu的2021/22年第一季度中期財務報告相關的交易窗口中行使。
Since 8 February 2022, instructions have been received to exercise warrants as follows:
自2022年2月8日以來，已收到如下行使認股權證的指示：
- 2 individuals have issued instructions to exercise 7,500 warrants at the agreed exercise price of DKK 77.12 per share with a nominal value of DKK 0.50.
- 2名個人已發出指示，將按商定的行權價每股77.12丹麥克朗行使7500份認股權證，票面價值為0.50丹麥克朗。
Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.
今天，Ambu董事會決定對已行使的認股權證進行增資。
As a result of the capital increase, the share capital of the Company's B shares will be increased by a nominal amount of DKK 3,750 from DKK 111,694,466 to DKK 111,698,216 through the issue of 7,500 Class B shares.
增資後，公司B股股本將通過發行7,500股B類股，增加面值3,750丹麥克朗，由111,694,466丹麥克朗增至111,698,216丹麥克朗。
Following this and in consideration of the employees having left the company, the following warrants remain under the said 2016 scheme:
在此之後，考慮到員工已經離開公司，根據上述2016年的計劃，以下認股權證仍然存在：
- 169,500 warrants being held by 25 individuals.
- 169,500份認股權證由25名個人持有。
The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 22 February 2022 under the ISIN code of Ambu A/S' existing B shares (DK0060946788).
預計新發行的B股將於2022年2月22日獲準在納斯達克哥本哈根A/S交易並正式掛牌，交易代碼為安步A/S現有B股ISIN碼(DK0060946788)。
Under section 32 of the Danish Capital Markets Act, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.
根據丹麥資本市場法第32條，Ambu A/S應在股本發生任何變化的一個月結束前公佈總股本和總投票權。下表顯示了增資後Ambu A/S的總股本和總投票權。
| Number of shares (nominal value DKK 0.50) |
Nominal value (DKK) |
Voting rights | |
| A shares | 34,320,000 | 17,160,000 | 343,200,000 |
| B shares | 223,396,432 | 111,698,216 | 223,396,432 |
| Total | 257,716,432 | 128,858,216 | 566,596,432 |
| 股份數量 (名義價值0.50丹麥克朗) |
名義價值 (DKK) |
投票權 | |
| A股 | 34,320,000 | 17,160,000 | 343,200,000 |
| B股 | 223,396,432 | 111,698,216 | 223,396,432 |
| 總計 | 257,716,432 | 128,858,216 | 566,596,432 |
Contact
聯繫人
Michael Højgaard, CFO, miho@ambu.com / +45 4030 4349
電子郵件：miho@ambu.com/+45 4030 4349
Ambu A/S
Baltorpbakken 13, DK-2750 Ballerup, Denmark, Tel.: +45 7225 2000, CVR no.: 63 64 49 19,
Ambu A/S
Baltorpbakken 13，DK-2750 Ballup，丹麥，電話：+45 7225 2000，電話：+45 7225 2000，CVR號碼：63 64 49 19，
About Ambu
Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world's first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,500 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com.
關於Ambu
自1937年以來，Ambu一直在將未來的解決方案帶入生活。今天，全球數以百萬計的患者和醫療保健專業人員依賴於我們的一次性內窺鏡檢查、麻醉以及患者監控和診斷解決方案的效率、安全性和性能。我們的努力體現了從早期的創新(如AMBU®BAG™復甦器和AMBU®BlueSensor™電極)到我們最新的標誌性解決方案，如AMBU®AScope™(全球首款一次性使用的柔性內窺鏡)。此外，我們繼續展望未來，致力於提供對醫生、護士和護理人員的工作產生積極影響的創新高質量產品。Ambu總部位於丹麥哥本哈根附近，在歐洲、北美和亞太地區擁有約4500名員工。欲瞭解更多信息，請訪問ambu.com。
Attachment
依附
- Company-announcement-no-7_2021-22
- 公司-公告-編號-7_2021-22
譯文內容由第三人軟體翻譯。